Autoimmune Thyroiditis and Vitamin D.
Study Goal
The researchers aimed to review the relationship between vitamin D status and Hashimoto's thyroiditis (HT) and assess the role of vitamin D supplementation in reducing HT risk by modulating the immune system.
Results Summary
The study found that vitamin D levels are significantly lower in HT patients compared to healthy individuals, and supplementation with cholecalciferol in deficient HT patients significantly reduced thyroid autoantibody titers. Further research is needed to confirm these benefits.
Population
Patients with Hashimoto's thyroiditis and vitamin D deficiency.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
vitamin D | decrease | vitamin D levels | HT patients compared to healthy people | - | are significantly lower | #1 |
supplementation with cholecalciferol | decrease | thyroid autoantibody titers | patients with HT and vitamin D deficiency | - | decreased significantly | #2 |
Hashimoto's thyroiditis (HT) is marked by self-tissue destruction as a consequence of an alteration in the adaptive immune response that entails the evasion of immune regulation. Vitamin D carries out an immunomodulatory role that appears to promote immune tolerance. The aim of this study is to elaborate a narrative review of the relationship between vitamin D status and HT and the role of vitamin D supplementation in reducing HT risk by modulating the immune system. There is extensive literature confirming that vitamin D levels are significantly lower in HT patients compared to healthy people. On the other hand, after the supplementation with cholecalciferol in patients with HT and vitamin D deficiency, thyroid autoantibody titers decreased significantly. Further knowledge of the beneficial effects of vitamin D in the prevention and treatment of autoimmune thyroid diseases requires the execution of additional randomized, double-blind, placebo-controlled trials and longer follow-up periods.